Use of 5&#945;-reductase inhibitors and survival of oesophageal and gastric cancer in a nationwide Swedish cohort study.

Rabbani, Sirus; Mattsson, Fredrik; Lagergren, Jesper; Xie, Shaohua

Use of 5α-reductase inhibitors and survival of oesophageal and gastric cancer in a nationwide Swedish cohort study.

Rabbani, Sirus; Mattsson, Fredrik; Lagergren, Jesper; Xie, Shaohua.

Afiliación

Rabbani S; Upper Gastrointestinal Surgery, Department of Molecular medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Mattsson F; Upper Gastrointestinal Surgery, Department of Molecular medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Lagergren J; Upper Gastrointestinal Surgery, Department of Molecular medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Xie S; School of Cancer and Pharmaceutical Sciences, King's College London, United Kingdom.

Acta Oncol ; 62(5): 438-443, 2023 May.

Article en En | MEDLINE | ID: mdl-37216488

Asunto(s)

Adenocarcinoma; Neoplasias Esofágicas; Neoplasias Gástricas; Masculino; Humanos; Estudios de Cohortes; Inhibidores de 5-alfa-Reductasa/uso terapéutico; Neoplasias Gástricas/tratamiento farmacológico; Suecia/epidemiología; Neoplasias Esofágicas/tratamiento farmacológico; Adenocarcinoma/patología; Oxidorreductasas

Palabras clave

5-alpha reductase inhibitors; Stomach neoplasms; gonadal steroid hormones; oesophageal neoplasms; prognosis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Adenocarcinoma Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male País/Región como asunto: Europa Idioma: En Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google